After several exuberant years in the European M&A markets; the party seems to be ending. Following a disappointing end to 2018, the worst half-yearly figure in five years, there’s some worry that dealmaking may continue to plummet.
The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.
European IPO markets rebounded in the second quarter from a dismal start to the year. The region saw 45 IPOs with a combined offering size of €12.69bn during the second quarter of 2019. Here are 5 trends that emerged during H1 2019.
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.